KALV — KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $1.4 million reported for EKTERLY during the launch period, primarily from stocking orders.
• Operating Expenses: Totaled $60.4 million, with $15 million in R&D and $45 million in SG&A, reflecting increased spending related to the EKTERLY launch.
• Cash Position: Approximately $191 million in cash and investments as of July 31, 2025, expected to fund operations into 2027.
• Fiscal Year Change: Transitioning to a calendar year-end, with the next report covering the quarter ending September 30, 2025.

2. Strategic Updates and Business Highlights

• FDA Approval: EKTERLY received FDA approval on July 7, 2025, as the first oral on-demand therapy for acute HAE attacks.
• Launch Metrics: Early uptake exceeded expectations, with nearly 5% of the U.S. HAE population submitting prescriptions within weeks of launch.
• International Expansion: Positive regulatory developments in Europe and the U.K., with anticipated launches in Germany and Japan in early 2026.
• Patient Engagement: Over 4,000 individuals joined the patient database, indicating strong community interest and engagement.

3. Forward Guidance and Outlook

• Continued Investment: Operating expenses expected to remain consistent as the company focuses on the EKTERLY launch.
• Market Growth: Anticipation of a staged launch in Europe and ongoing discussions with potential partners worldwide, which could drive long-term growth.
• KPI Evolution: Future reports will adjust key performance indicators as the launch progresses, including tracking prescription refills and patient utilization.

4. Bad News, Challenges, or Points of Concern

• Access Challenges: Formal coverage policies may take up to six months to establish, with some patients facing prior authorization hurdles.
• Insurance Dynamics: Some payers may require step-through protocols with generic therapies before approving EKTERLY, although most patients have transitioned smoothly to EKTERLY.
• Market Competition: Potential competitive pressures from existing therapies and the need to establish a strong market presence amid evolving payer policies.

5. Notable Q&A Insights

• Quickstart Program: Patients receive immediate access to EKTERLY at no charge while the company works on securing paid access through medical exceptions.
• Patient Profiles: Early adopters include a broad range of patients, particularly those with a high burden of disease, which aligns with market research expectations.
• Reimbursement Insights: Initial anecdotal feedback indicates a positive trajectory for securing paid prescriptions, with some patients already receiving refills.
• Adverse Events: Minimal reports of side effects have been observed, aligning with previous clinical data, indicating a favorable safety profile for EKTERLY.

Overall, KalVista's Q1 2026 earnings call highlighted a strong start for EKTERLY, with positive early adoption metrics and strategic plans for expansion, while also addressing challenges related to insurance coverage and market competition.